Self-administered intermittent mushroom dosing associated with multi-year OCD symptom relief

Source note

Anonymised summary of Wilcox (2014), Journal of Psychoactive Drugs. The original author did not endorse self-medication; the report was published to motivate controlled research.

Participant profile (non-identifying)

• Age / sex: 38-year-old male
• Body weight: approximately 77 kg (170 lb)
• Presentation: chronic anxiety with counting rituals, intrusive thoughts, and repetitive checking routines; multiple failed psychotherapy modalities before psychedelic use

Reported pattern of use

• First exposure via dried “magic mushrooms” from a social contact
• Acute anxiety rose during intoxication, but intrusive thoughts were markedly reduced the next day
• Subsequent self-titration to roughly 2 g dried mushrooms approximately every three weeks, with reported multi-year maintenance of reduced obsessions/compulsions and anxiety

Limitations (critical)

• Species, alkaloid content, and exact milligram psilocybin dose were not verified
• Uncontrolled setting; recall and expectancy bias are likely
• Illegal/unregulated supply risks (contamination, misidentification, legal exposure) are not mitigated by symptom reports

Why included

Documents a long-horizon anecdotal OCD signal that later clinical programmes attempt to test under GMP dosing and ethics oversight. Not a treatment recommendation.